Zhejiang Tianyu Pharmaceutical Co., Ltd. (SHE:300702)
China · Delayed Price · Currency is CNY 21.31
+0.07 (0.33%)
Apr 29, 2026, 3:04 PM CST
SHE:300702 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 3,113 | 3,061 | 2,615 | 2,521 | 2,651 | 2,529 |
Other Revenue | - | - | 15.64 | 6.74 | 15.33 | 16.49 |
| 3,113 | 3,061 | 2,631 | 2,527 | 2,667 | 2,545 | |
Revenue Growth (YoY) | 15.29% | 16.36% | 4.10% | -5.23% | 4.78% | -1.64% |
Cost of Revenue | 1,999 | 1,926 | 1,761 | 1,677 | 2,076 | 1,638 |
Gross Profit | 1,115 | 1,135 | 869.86 | 849.83 | 591.07 | 907.42 |
Selling, General & Admin | 597.76 | 584.11 | 500.32 | 425.45 | 423.79 | 465.02 |
Research & Development | 239.76 | 240.31 | 238.9 | 243.82 | 231.1 | 227.4 |
Other Operating Expenses | 10.59 | 6.66 | 20.91 | 28.17 | 19.72 | 24.14 |
Operating Expenses | 848.12 | 831.08 | 758.76 | 703.74 | 670.74 | 721.58 |
Operating Income | 266.81 | 304.4 | 111.1 | 146.09 | -79.67 | 185.84 |
Interest Expense | - | - | -54.07 | -49.91 | -33.85 | -16.33 |
Interest & Investment Income | 0.63 | - | 19.88 | 6.07 | 7.22 | 75.73 |
Currency Exchange Gain (Loss) | - | - | 25.18 | 8.83 | 37.92 | -10.58 |
Other Non Operating Income (Expenses) | -81.47 | -62.05 | -4.85 | -2.3 | -1.28 | -1.12 |
EBT Excluding Unusual Items | 185.97 | 242.34 | 97.24 | 108.78 | -69.66 | 233.55 |
Gain (Loss) on Sale of Investments | 0.98 | 0.95 | -30.4 | -62.69 | -59.65 | -12.97 |
Gain (Loss) on Sale of Assets | 1.2 | -0.43 | 0.72 | -0.03 | -0.02 | 0.06 |
Asset Writedown | -79.05 | -84.26 | -2.67 | -2.09 | -8.21 | -16.09 |
Other Unusual Items | - | - | 13.75 | 27.64 | 26.76 | 13.85 |
Pretax Income | 109.1 | 158.6 | 78.64 | 71.92 | -110.5 | 218.41 |
Income Tax Expense | 13.38 | 18.89 | 22.7 | 44.56 | 8.37 | 13.73 |
Net Income | 95.72 | 139.71 | 55.94 | 27.36 | -118.87 | 204.68 |
Net Income to Common | 95.72 | 139.71 | 55.94 | 27.36 | -118.87 | 204.68 |
Net Income Growth | -5.79% | 149.78% | 104.45% | - | - | -69.32% |
Shares Outstanding (Basic) | 341 | 341 | 350 | 342 | 350 | 347 |
Shares Outstanding (Diluted) | 341 | 341 | 350 | 342 | 350 | 347 |
Shares Change (YoY) | -2.50% | -2.53% | 2.22% | -2.18% | 0.78% | 6.61% |
EPS (Basic) | 0.28 | 0.41 | 0.16 | 0.08 | -0.34 | 0.59 |
EPS (Diluted) | 0.28 | 0.41 | 0.16 | 0.08 | -0.34 | 0.59 |
EPS Growth | -3.37% | 156.25% | 100.00% | - | - | -71.22% |
Free Cash Flow | 219.45 | 115.8 | 175.69 | -360.71 | -575.71 | -998.62 |
Free Cash Flow Per Share | 0.64 | 0.34 | 0.50 | -1.05 | -1.65 | -2.88 |
Dividend Per Share | - | - | 0.050 | 0.050 | - | 0.100 |
Dividend Growth | - | - | - | - | - | -64.00% |
Gross Margin | 35.81% | 37.09% | 33.06% | 33.63% | 22.17% | 35.66% |
Operating Margin | 8.57% | 9.94% | 4.22% | 5.78% | -2.99% | 7.30% |
Profit Margin | 3.07% | 4.56% | 2.13% | 1.08% | -4.46% | 8.04% |
Free Cash Flow Margin | 7.05% | 3.78% | 6.68% | -14.27% | -21.59% | -39.24% |
EBITDA | 622.25 | 653.02 | 432.5 | 439.74 | 164.56 | 371.04 |
EBITDA Margin | 19.99% | 21.33% | 16.44% | 17.40% | 6.17% | 14.58% |
D&A For EBITDA | 355.44 | 348.63 | 321.4 | 293.65 | 244.23 | 185.2 |
EBIT | 266.81 | 304.4 | 111.1 | 146.09 | -79.67 | 185.84 |
EBIT Margin | 8.57% | 9.94% | 4.22% | 5.78% | -2.99% | 7.30% |
Effective Tax Rate | 12.27% | 11.91% | 28.87% | 61.96% | - | 6.29% |
Revenue as Reported | - | - | 2,631 | 2,527 | 2,667 | 2,545 |
Advertising Expenses | - | - | 61.43 | 67.59 | 12.92 | 0.97 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.